Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases
- CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company working to change what is possible for people living with T cell-driven autoimmune diseases, announced it is leveraging its validated T cell-directed lipid nanoparticle (ctLNP) to develop siRNA therapeutics to silence disease-driving targets in T cells. “We are excited to move Generation Bio toward the clinic by deploying our ctLNP to deliver siRNA to T cells. By precisely modulating T cell activity in vivo we believe we can address high-value, currently undruggable targets involved in the inflammation and tissue damage associated with T cell-driven autoimmune diseases,” said Geoff McDonough, M.D., chief executive officer of Generation Bio. “Our aim is to silence therapeutic T cell targets without impacting other immune cell types, unlocking a powerful new application for siRNA in the field. We plan to submit our first IND in the second half of 2026 and to enter the clinic within our cash runway, which is into the second half of 2027.”
- 01/06/2025
|
Generation Bio Co. (GBIO) Reports Q3 Loss, Tops Revenue Estimates
- Generation Bio Co. (GBIO) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.43 per share a year ago.
- 11/06/2024
|
Generation Bio Announces the Presentation of Preclinical Data on ctLNP and iqDNA at the ESGCT 31st Annual Congress
- CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today presented data on its cell-targeted lipid nanoparticle (ctLNP) and immune-quiet DNA (iqDNA) platforms at the European Society of Gene and Cell Therapy (ESGCT) 31st Annual Congress.
- 10/22/2024
|
Generation Bio to Present at the 2024 Cantor Global Healthcare Conference
- CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024 at 10:20 a.m. ET in New York.
- 09/12/2024
|
Generation Bio Co. (GBIO) Reports Q2 Loss, Tops Revenue Estimates
- Generation Bio Co. (GBIO) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.47 per share a year ago.
- 08/07/2024
|
Generation Bio to Present at the Canaccord Genuity 44th Annual Growth Conference
- CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13th, 2024 at 2:30 p.m. ET in Boston.
- 08/06/2024
|
Generation Bio to Present at the 2024 TD Cowen Genetic Medicines & RNA Summit
- CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the virtual 2024 TD Cowen Genetic Medicines & RNA Summit on Friday, June 21st, 2024 at 1:50 p.m. ET.
- 06/14/2024
|
Cofi.ai Names Aaron Kizer President and Equity Partner
- AUSTIN, TX/ ACCESSWIRE / May 20, 2024 / Cofi.ai, a groundbreaking financial planning and analysis software built for VC/PE and SMB tech companies, announced today that Aaron Kizer has joined the company as President. As the company continues to accelerate its growth, Aaron will spearhead strategy and product at Cofi.ai globally.Logo Company logoMr. Kizer brings over 30 years of experience in technology, having spent more than 12 years at Workiva. During his tenure at Workiva, he focused on data security, services, pre-sales, product management, and R&D operations on a global scale. Aaron had the unique advantage of being part of Workiva's early startup days when it was known as Webfilings, giving him direct experience growing a SAAS company from startup to a global platform that went public."I am excited about the opportunity to streamline report creation and provide finance professionals with better insights for analysis. My passion for cutting-edge technology dovetails perfectly with Cofi.ai's mission to leverage AI thoughtfully and impactfully in the industry," said Kizer.Before joining Workiva, Mr. Kizer managed a professional services group at Dell Computer Corp. He also served as the Chief Technology Officer of Generation Bridge, overseeing development, infrastructure, and security. Additionally, he spent two years as the Director of Business Development for Radio Shack, where he identified and brought innovative products to the company.Alex Irigoyen, co-founder and CEO of Cofi.ai, said: "Welcoming Aaron Kizer as President marks a key milestone for Cofi.ai. His expertise in tech and finance, and his clear strategic vision, will help us grow and innovate more than ever. Aaron brings proven experience in SaaS coupled with a strong industry background that will help drive us forward and support the industry's growing needs. I am pleased to welcome him to our team and look forward to seeing the positive impact he makes."Aaron has his BS from Texas A&M and lives in Austin, Texas, with his family.About Cofi.ai -Cofi.ai's focuses on automating FP&A reporting for PE, VC and SMB technology companies. Our mission is to democratize data-driven decision-making across all types of organizations, regardless of their size and budget. Our vision is to improve decision-making by combining AI and human intelligence to help every business thrive. Cofi.ai plans to expand its executive team by adding several key individuals this year to drive the company forward.Contact InformationMichelle Amato michelle.amato@cofi.ai 7735055136Related ImagesLogo Company logoAaron Kizer Exec photoSOURCE: Cofi.aiView the original press release on newswire.com.
- 05/20/2024
|
Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates
- Generation Bio Co. (GBIO) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.53 per share a year ago.
- 05/13/2024
|
Generation Bio Announces Recent Business Highlights and First Quarter 2024 Financial Results
- - Oral presentation at ASGCT described selective, high levels of therapeutic transgene delivery to T cells in vivo by cell-targeted lipid nanoparticle (ctLNP)
- 05/13/2024
|
Generation Bio Announces the Presentation of Preclinical Data on iqDNA and ctLNP Platforms at the ASGCT 27th Annual Meeting
- CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today presented five posters on its immune-quiet DNA (iqDNA) and cell-targeted lipid nanoparticle (ctLNP) platforms as well as its enzymatic synthesis manufacturing at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting. A sixth presentation on the company's ctLNP platform will be discussed in an oral presentation on Saturday, May 11.
- 05/09/2024
|
Generation Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
- CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today announced that six abstracts highlighting preclinical data from its cell-targeted lipid nanoparticle (ctLNP) and immune-quiet DNA (iqDNA) platforms have been accepted for presentation, including one oral presentation, at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place May 7-11, 2024 in Baltimore, MD.
- 04/22/2024
|
Generation Bio to Present at the 23rd Annual Needham Virtual Healthcare Conference
- CAMBRIDGE, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024 at 12:45 p.m. ET.
- 04/02/2024
|
Generation Bio Co. (GBIO) Reports Q4 Loss, Lags Revenue Estimates
- Generation Bio Co. (GBIO) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.55 per share a year ago.
- 03/06/2024
|
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
- - Company is leveraging proprietary cell-targeted lipid nanoparticle delivery to develop wholly-owned in vivo program for sickle cell disease and beta-thalassemia
- 03/06/2024
|
Generation Bio to Present at the 2024 TD Cowen Health Care Conference
- CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the 2024 TD Cowen Health Care Conference on Tuesday, March 5, 2024 at 9:10 a.m. ET in Boston.
- 02/27/2024
|
Generation Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 3:45 p.m. PT in San Francisco.
- 01/03/2024
|
3 Penny Stocks To Buy According To Insiders In December
- Penny stocks – the cheap stocks trading under $5 per share, offer investors massive upside potential alongside higher risk. Since even incremental price moves translate into huge percentage gains in the stock market, timing entries right can set you up for explosive profits.
- 12/07/2023
|
Generation Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA Platforms
- CAMBRIDGE, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced a strategic reorganization to prioritize investment in the development of its cell-targeted lipid nanoparticle (ctLNP) delivery system for wholly-owned programs in extrahepatic cell types. Generation Bio intends to continue to develop ctLNP for immune cells as part of its collaboration with Moderna and to develop its immune-quiet DNA (iqDNA) for its lead hemophilia A and other programs.
- 11/29/2023
|
Generation Bio Reports Business Highlights and Third Quarter 2023 Financial Results
- - Immune-quiet DNA evades innate immune sensors in both mice and non-human primates addressing a central challenge for non-viral DNA therapeutics
- 11/09/2023
|
Generation Bio Announces Demonstration of Highly Selective T Cell Transduction In Vivo with Cell-Targeted LNP Platform
- CAMBRIDGE, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that it has reached two significant achievements through in vivo studies, including results generated as part of its collaboration with Moderna, Inc. First, Generation Bio has shown highly selective T cell targeting in vivo with its cell-targeted LNP (ctLNP) platform in a humanized mouse model. Separately, the company has confirmed the stealth properties of its ctLNP platform in non-human primates (NHPs). Generation Bio will present these data at the European Society for Gene and Cell Therapy (ESGCT) 30th Annual Congress in Brussels, Belgium at 4:40 p.m. CEST today. Slides from the presentation will be made available on Generation Bio's website following the presentation.
- 10/26/2023
|
Top 4 Health Care Stocks That May Rocket Higher This Month - Generation Bio (NASDAQ:GBIO), Evelo Biosciences (NASDAQ:EVLO)
- The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
- 10/20/2023
|
Generation Bio Announces Breakthrough in its Non-Viral Genetic Medicine Platform with Novel “Immune-Quiet” DNA
- – Immune-quiet DNA (iqDNA) is a novel variant of closed-ended DNA (ceDNA) that evades host innate immune detection in both mice and non-human primates (NHPs) with a systemic cytokine profile and tolerability comparable to mRNA
- 10/18/2023
|
Generation Bio to Present at the Jefferies Cell & Genetic Medicine Summit
- CAMBRIDGE, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the Jefferies Cell & Genetic Medicine Summit on Tuesday, September 26, 2023 at 9:30 a.m. ET in New York.
- 09/19/2023
|
Generation Bio to Present at the Canaccord Genuity 43rd Annual Growth Conference
- CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Matt Norkunas, M.D., chief financial officer, will present at the 2023 Canaccord Healthcare Conference on Thursday, August 10, 2023 at 11:00 a.m. ET in Boston.
- 08/03/2023
|
Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates
- Generation Bio Co. (GBIO) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.66 per share a year ago.
- 08/02/2023
|
Generation Bio Reports Second Quarter 2023 Financial Results
- Second quarter 2023 cash balance of $314.1 million expected to fund operations into 2025 Second quarter 2023 cash balance of $314.1 million expected to fund operations into 2025
- 08/02/2023
|
Generation Bio to Present at the 2023 Jefferies Healthcare Conference
- CAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the 2023 Jefferies Healthcare Conference Wednesday, June 7, 2023 at 1:30 p.m. EST in New York.
- 05/31/2023
|
Generation Bio Co. (GBIO) Reports Q1 Loss, Misses Revenue Estimates
- Generation Bio Co. (GBIO) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.61 per share a year ago.
- 05/10/2023
|
Generation Bio to Present at the JMP Securities Life Sciences Conference
- CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Matt Norkunas, M.D., chief financial officer, will present at the JMP Securities Life Sciences on Tuesday, May 16, 2023 at 1:00 p.m. EST in New York.
- 05/09/2023
|
Generation Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference
- CAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare on Tuesday, April 18th at 3:00 p.m. EST.
- 04/11/2023
|
Best Penny Stocks To Buy Now? 10 To Watch Under $5
- Penny stocks to watch this week under $5 The post Best Penny Stocks To Buy Now? 10 To Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 03/24/2023
|
Penny Stocks To Buy Under $5? 7 To Watch This Week
- Penny stocks to watch under $5 this week. The post Penny Stocks To Buy Under $5?
- 03/23/2023
|
Generation Bio, Moderna announce collaboration
- Shares of Generation Bio Co. GBIO, -0.51% jumped about 28% premarket trading on Thursday after the company announced a collaboration with Moderna Inc. MRNA, -2.58% to to develop novel nucleic acid therapeutics. Moderna will make an upfront payment of $40 million in cash, in addition to a $36 million equity investment “at a premium over recent share prices.
- 03/23/2023
|
Generation Bio to Present at the 43rd Annual Cowen Healthcare Conference
- CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in the Gene Therapy panel discussion at the 43rd Annual Cowen Healthcare Conference on Monday, March 6th at 10:30 a.m. EST in Boston, MA.
- 02/27/2023
|
Generation Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
- CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10th at 4:30 p.m. PST in San Francisco, CA.
- 01/03/2023
|
Generation Bio to Present at the 2022 Jefferies Cell and Genetic Medicine Summit
- CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will participate in a fireside chat at the 2022 Jefferies Cell & Genetic Medicine Summit on Thursday, September 29th at 10:30 a.m. ET in New York.
- 09/22/2022
|
Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates
- Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -4.76% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/04/2022
|
Generation Bio to Present at the 2022 Wedbush PacGrow Healthcare Conference
- CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will participate in a panel at the virtual 2022 Wedbush PacGrow Healthcare Conference on Tuesday, August 9th at 9:45 a.m. ET.
- 08/02/2022
|
Wall Street Analysts See a 174% Upside in Generation Bio Co. (GBIO): Can the Stock Really Move This High?
- The average of price targets set by Wall Street analysts indicates a potential upside of 173.7% in Generation Bio Co. (GBIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 07/11/2022
|
Generation Bio to Present at the 2022 Jefferies Healthcare Conference
- CAMBRIDGE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 2022 Jefferies Healthcare Conference on Friday, June 10th at 11:00 a.m. ET in New York.
- 06/02/2022
|
Generation Bio to Present at 40th Annual J.P. Morgan Healthcare Conference
- CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that the company will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 12, 2022.
- 01/05/2022
|
Generation Bio Hits 52-Week Low After Preclinical Data From Hemophilia A Program
- Generation Bio Co (NASDAQ: GBIO) provided an update on factor VIII expression from a series of mouse and companion non-human primate (NHP) studies in hemophilia A and an update on its development non-viral genetic medicine platform. In mouse studies, rapid enzymatic synthesis (RES)-derived ceDNA delivered by ctLNP generated peak mean human factor VIII expression of 205% of normal at 2.0 mg/kg.
- 12/14/2021
|
Generation Bio to Present at Jefferies Virtual Gene Therapy/Editing Summit
- CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the Jefferies Virtual Gene Therapy/Editing Summit on Wednesday, October 27 at 5:00 p.m. ET.
- 10/21/2021
|
Generation Bio to Present at European Society of Gene and Cell Therapy 2021 Annual Virtual Congress
- CAMBRIDGE, Mass., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today announced an oral presentation at the European Society of Gene and Cell Therapy (ESGCT) Annual Virtual Congress taking place October 19-22. The presentation will highlight preclinical advances from the company's retina therapeutic area.
- 10/15/2021
|
Generation Bio Reports Business Highlights and Second Quarter 2021 Financial Results
- CAMBRIDGE, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported recent business highlights and second quarter 2021 financial results.
- 08/11/2021
|
Generation Bio to Present at Wedbush PacGrow Healthcare Conference 2021
- CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that Geoff McDonough, M.D., president and chief executive officer, will participate in a panel discussion at the Wedbush PacGrow Healthcare Conference 2021 on Tuesday, August 10 at 9:10 a.m. ET.
- 08/03/2021
|
Generation Bio Announces Plan to Scale Next-Generation Rapid Enzymatic Manufacturing Process Across Portfolio and Provides Pipeline Update
- Company to transition all portfolio programs to rapid enzymatic synthesis (RES), enabling improved quality, scale and speed of closed-ended DNA manufacturing
- 07/14/2021
|
Generation Bio to Present at William Blair Biotech Focus Conference
- CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff McDonough, M.D., president and chief executive officer, will present at the William Blair Biotech Focus Conference 2021 on Thursday, July 15, at 9:00 a.m. ET.
- 07/08/2021
|
Generation Bio to Present at the JMP Securities Life Sciences Conference
- CAMBRIDGE, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff McDonough, M.D., president and chief executive officer, will present at the JMP Securities Life Sciences Conference on Wednesday, June 16, at 11:30 a.m. ET.
- 06/09/2021
|
Generation Bio to Present at the Jefferies Virtual Healthcare Conference
- CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff McDonough, M.D., president and chief executive officer, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, at 11:30 a.m. ET.
- 05/27/2021
|
Generation Bio Presents Preclinical Data Demonstrating Broad Potential of Gene Therapy Platform at ASGCT and Reports First Quarter Financial Results
- Durable, therapeutically relevant levels of anti-SARS-CoV-2 spike antibodies produced from the liver in a mouse model
- 05/12/2021
|
Generation Bio to Present at American Society of Gene & Cell Therapy 2021 Virtual Annual Meeting
- CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today announced three digital presentations at the American Society of Gene & Cell Therapy (ASGCT) 2021 Virtual Annual Meeting taking place May 11-14. The presentations will cover data supporting use of the company's platform for antibody gene therapy, a summary of previously released preclinical data from the hemophilia A program and insight into ceDNA construct engineering for factor VIII.
- 04/27/2021
|
Generation Bio to Present at 20th Annual Needham Virtual Healthcare Conference
- CAMBRIDGE, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, at 3:00 p.m. ET.
- 04/08/2021
|
Why Earnings Season Could Be Great for Generation Bio (GBIO)
- Generation Bio (GBIO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 03/01/2021
|
Generation Bio: Pioneering A New Class Of Gene Therapy
- Generation Bio is a stock to monitor for its potential to disrupt the viral gene therapy market. The company is centered around a technology platform that creates non-viral gene therapies that are re-dosable and have the COGs of a biologic.
- 02/24/2021
|
Abercrombie, Mattel, Western Digital and More Wednesday Afternoon Analyst Calls
- With the trading day more than halfway over, the broad markets have pushed higher, seemingly recovering from Tuesday.
- 02/24/2021
|
Generation Bio Appoints Ron Cooper to Its Board of Directors
- CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, announced today that Ron Cooper has been appointed to its Board of Directors. The appointment is effective March 1, 2021.
- 02/18/2021
|
Notable Insider Buys Of The Past Week: Conagra Brands Plus Plenty Of Biotech Activity
- Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly when there is uncertainty in the markets, as there has been due to the pandemic resurgence and political issues.
- 01/16/2021
|
Generation Bio Announces Closing of Public Offering
|
Generation Bio Announces Pricing of Public Offering
- CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the pricing of a public offering of 8,000,000 shares of its common stock at a public offering price of $24.50 per share. In addition, Generation Bio has granted the underwriters a 30-day option to purchase up to 1,200,000 additional shares of common stock at the public offering price, less the underwriting discount and commissions. All of the shares are being offered by Generation Bio.
- 01/06/2021
|
Generation Bio (GBIO) Catches Eye: Stock Jumps 6.1%
- Generation Bio (GBIO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
- 01/05/2021
|
Generation Bio to Present at 39th Annual J.P. Morgan Healthcare Conference
- CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that the company will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 12, 2021.
- 01/05/2021
|
Generation Bio Announces Two Non-Viral Gene Therapy Milestone Achievements: Target Levels of Factor VIII Expression in Hemophilia A Mice and Translation of Expression from Mice to Non-Human Primates
- Data confirm delivery of closed-ended DNA to the liver via novel, cell-targeted lipid nanoparticles
- 01/04/2021
|
U.S. IPO Week Ahead: DoorDash And Airbnb Kick Off The Unicorn Parade In A 6 IPO Week
- The unicorn IPO parade is set to begin in the week ahead, with DoorDash and Airbnb leading the way. A total of six IPOs and two SPACs are scheduled to raise $7.2 billion.
- 12/06/2020
|
Generation Bio Reports Third Quarter 2020 Business Updates and Financial Results
- On Track to Advance Lead Programs into Pre-Clinical Development in 2021 Supported by Key Leadership Team Appointments On Track to Advance Lead Programs into Pre-Clinical Development in 2021 Supported by Key Leadership Team Appointments
- 11/10/2020
|
Generation Bio Reports Business Updates and Second Quarter 2020 Financial Results
- CAMBRIDGE, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today reported recent business highlights and second quarter financial results. “The first half of 2020 has seen meaningful progress for Generation Bio, punctuated by the recent successful completion of our initial public offering,” said Geoff McDonough, M.D., president and chief executive officer of Generation Bio. “Our team continues to advance our science with efficiency, despite the uncertainties with the COVID-19 pandemic. Combined with our strong balance sheet, we are well-positioned to further develop our diverse portfolio for both rare and prevalent diseases.”Recent Business Highlights * Appointment of Matthew Norkunas, M.D., MBA as Chief Financial Officer: In July 2020, Generation Bio further strengthened its leadership team with the appointment of Dr. Norkunas, to chief financial officer. Previously, Dr. Norkunas served as chief financial officer at SomaLogic, Inc., and as a senior equity analyst at Marsico Capital Management. Dr. Norkunas began his career as a practicing anesthesiologist, after receiving a B.A. from St. Mary’s College of Maryland, an M.D. from the University of Maryland School of Medicine, and later received an MBA from Columbia Business School. * $230 Million Initial Public Offering (IPO) Successfully Completed: On June 16, 2020, Generation Bio sold 12,105,263 shares of common stock at an initial public offering price of $19.00 per share in its IPO, including 1,578,947 additional shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. The gross proceeds of the offering, before deducting the underwriting discount and commissions and other offering expenses payable by Generation Bio, were approximately $230.0 million. Second Quarter 2020 Financial Results * Cash Position: Cash, cash equivalents and marketable securities were $301.1 million as of June 30, 2020, which includes the $230.0 million in gross proceeds from the company’s IPO completed in June 2020. * R&D Expenses: Research and development (R&D) expenses were $13.5 million for the quarter ended June 30, 2020 compared to $12.2 million for the same period of 2019. * G&A Expenses: General and administrative (G&A) expenses were $4.3 million for the quarter ended June 30, 2020 compared to $3.1 million for the same period of 2019. * Net Loss: Net loss was $17.7 million for the quarter ended June 30, 2020 compared to $15.0 million for the same period of 2019.About Generation BioGeneration Bio is an innovative genetic medicines company focused on creating a new class of non-viral gene therapy to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral platform incorporates a proprietary, high-capacity DNA construct called closed-ended DNA, or ceDNA; a cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The platform is designed to enable multi-year durability from a single dose of ceDNA and to allow titration and redosing if needed. The ctLNP is designed to deliver large genetic payloads, including multiple genes, to specific tissues to address a wide range of indications. The company’s efficient, scalable manufacturing process supports Generation Bio’s mission to extend the reach of gene therapy to more people, living with more diseases, in more places around the world.For more information, please visit www.generationbio.com.Forward-Looking StatementsAny statements in this press release about future expectations, plans and prospects for the Company, including statements about its strategic plans or objectives, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the conduct of research activities, the initiation and completion of preclinical studies and clinical trials and clinical development of the Company’s product candidates; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials; expectations for regulatory approvals to conduct trials or to market products; challenges in the manufacture of genetic medicine products; the Company’s ability to obtain sufficient cash resources to fund the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; the impact of the COVID-19 pandemic on the Company’s business and operations; as well as the other risks and uncertainties set forth in the “Risk Factors” section of the Company’s final prospectus for its initial public offering filed pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended with the Securities and Exchange Commission, the Company’s most recent quarterly report on Form 10-Q, which will be filed with the Securities and Exchange Commission, and in subsequent filings the Company may make with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date on which they were made.Contacts:Investors Chelcie Lister THRUST Strategic Communications chelcie@thrustsc.com 910-777-3049Media Stephanie Simon Ten Bridge Communications stephanie@tenbridgecommunications.com 617-581-9333GENERATION BIO CO. CONSOLIDATED BALANCE SHEET DATA (unaudited) (in thousands) June 30, 2020 December 31, 2019 Cash, cash equivalents and marketable securities $301,086 $15,076 Working capital 294,641 8,998 Total assets 331,202 42,140 Convertible preferred stock — 115,593 Total stockholders' equity (deficit) 304,153 (98,592) GENERATION BIO CO. CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (in thousands, except share and per share data) Three Months Ended June 30, 2020 2019 Operating expenses: Research and development $13,456 $12,237 General and administrative 4,308 3,098 Total operating expenses 17,764 15,335 Loss from operations (17,764) (15,335) Other income (expense): Interest income and other income (expense), net 33 303 Net loss and net loss attributable to common stockholders $(17,731) $(15,032) Net loss per share attributable to common stockholders, basic and diluted $(1.50) $(3.30) Weighted average common shares outstanding, basic and diluted 11,801,704 4,557,517
- 08/11/2020
|
Generation Bio to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
- CAMBRIDGE, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today announced that management will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, Aug. 12, 2020 at 10:20 a.m. ET. A live webcast of the company presentation will be available in the investor section of the company's website at www.generationbio.com. The webcast will be archived for 60 days following the presentation.About Generation Bio Generation Bio is an innovative genetic medicines company focused on creating a new class of non-viral gene therapy to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral platform incorporates a proprietary, high-capacity DNA construct called closed-ended DNA, or ceDNA; a cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The platform is designed to enable multi-year durability from a single dose of ceDNA and to allow titration and redosing if needed. The ctLNP is designed to deliver large genetic payloads, including multiple genes, to specific tissues to address a wide range of indications. The company’s efficient, scalable manufacturing process supports Generation Bio’s mission to extend the reach of gene therapy to more people, living with more diseases, in more places around the world.For more information, please visit www.generationbio.com. Contact:Investors Chelcie Lister THRUST Strategic Communications chelcie@thrustsc.com 910-777-3049Media Stephanie Simon Ten Bridge Communications stephanie@tenbridgecommunications.com 617-581-9333
- 08/05/2020
|
Generation Bio Appoints Matthew Norkunas, M.D., MBA as Chief Financial Officer
- CAMBRIDGE, Mass., July 22, 2020 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today announced that Matthew Norkunas, M.D., MBA, has been appointed chief financial officer. “We are delighted to add Matt’s broad strategic perspective and deep operational experience to our team as we prepare the platform for our journey to the clinic,” said Geoff McDonough, M.D., president and chief executive officer of Generation Bio.Dr. Norkunas most recently served as CFO at SomaLogic, Inc., a Colorado-based biotech that uses a proprietary protein scan to evaluate health and assess disease risk. Prior to that, Dr. Norkunas was senior equity analyst at Marsico Capital Management, where he served as the firm’s primary health care investment specialist. Dr. Norkunas began his career as a practicing anesthesiologist. He received his B.A. from St. Mary’s College of Maryland, his M.D. from University of Maryland School of Medicine, and his MBA from Columbia Business School.“I have long believed that precision medicine has the power to transform our world, and I’m excited to join a team that is developing a way to do that at scale,” Dr. Norkunas said. “Generation Bio’s non-viral platform is designed to extend the reach of gene therapy to people living with both rare and prevalent diseases. I am looking forward to helping shape and support the company’s growth.”About Generation BioGeneration Bio is an innovative genetic medicines company focused on creating a new class of non-viral gene therapy to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral platform incorporates a proprietary, high-capacity DNA construct called closed-ended DNA, or ceDNA; a cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The platform is designed to enable multi-year durability from a single dose of ceDNA, and to allow titration and redosing if needed. The ctLNP is designed to deliver large genetic payloads, including multiple genes, to specific tissues to address a wide range of indications. The company’s efficient, scalable manufacturing process supports Generation Bio’s mission to extend the reach of gene therapy to more people, living with more diseases, in more places around the world.For more information, please visit www.generationbio.com.Contact:Investors Monique Allaire THRUST Strategic Communications monique@thrustsc.com 617-895-9511Media Stephanie Simon Ten Bridge Communications stephanie@tenbridgecommunications.com 617-581-9333
- 07/22/2020
|
Stocks To Watch: Postmates, Walgreens And Cannabis Plays
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
- 07/04/2020
|
Generation Bio Announces Closing of Initial Public Offering
- Generation Bio Co. (GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the closing of its initial public offering of 12,105,263 shares of its common stock at an initial public offering price of $19.00 per share, including 1,578,947 additional shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. All of the shares in the offering were sold by Generation Bio. The shares began trading on the Nasdaq Global Select Market on Friday, June 12, 2020 under the ticker symbol “GBIO.”
- 06/16/2020
|
Generation Bio shares soar 23% in trading debut
- Shares of Generation Bio Inc., a biotech that specializes in gene therapy treatments for rare diseases, soared 23% Friday in their trading debut, after the IPO was upsized and priced at $19 a share, the high end of its price range. The company sold 10.5 million shares to raise $199.5 million. The shares are trading on Nasdaq, under the ticker symbol "GBIO." J.P. Morgan, Jefferies, Cowen and Wedbush PacGrow were underwriters on the deal. Proceeds will be used to fund R&D;, to develop platform technologies and for general corporate purposes. "We are an innovative genetic medicines company creating a new class of gene therapy utilizing our proprietary non-viral gene therapy platform to provide durable, redosable treatments for millions of patients living with rare and prevalent diseases," the company says in its prospectus.
- 06/12/2020
|
Generation Bio prices upsized IPO at $19 a share to raise $199.5 million
- Generation Bio Inc., a biotech that specializes in gene therapy treatments for rare diseases, priced its upsized initial public offering at $19 a share, the high end of its price range. The company sold 10.5 million shares to raise $199.5 million. The shares will starting trading on Nasdaq later Friday, under the ticker symbol "GBIO." J.P. Morgan, Jefferies, Cowen and Wedbush PacGrow were underwriters on the deal. Proceeds will be used to fund R&D;, to develop platform technologies and for general corporate purposes. "We are an innovative genetic medicines company creating a new class of gene therapy utilizing our proprietary non-viral gene therapy platform to provide durable, redosable treatments for millions of patients living with rare and prevalent diseases," the company says in its prospectus.
- 06/12/2020
|
Generation Bio Announces Pricing of Initial Public Offering
- CAMBRIDGE, Mass., June 11, 2020 -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the pricing.
- 06/12/2020
|
